Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$256.00K$256.00K−76.5% vs Q2 2021 Net Income-$29.49M-$29.49MN/M vs Q2 2021 EPS Diluted-$1.06-$1.06N/M vs Q2 2021 Operating Income-$29,564,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$18,378,000N/M Margins · derivedOperating margin-11548.4%−9897.2 pt vs Q2 2021
Net margin-11519.9%−9871.8 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end